aTyr Pharma's Efzofitimod Fails to Meet Goals in Pulmonary Sarcoidosis Trial
TL;DR Summary
aTyr Pharma's Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed clinical benefits such as improved lung scores and steroid withdrawal, leading the company to plan discussions with the FDA on future development.
Topics:business#clinical-trial#efzofitimod#fda-engagement#healthcare#pulmonary-sarcoidosis#steroid-reduction
- aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis GlobeNewswire
- aTyr Pharma (NASDAQ:ATYR) Stock Price Up 7.5% - Still a Buy? MarketBeat
- aTyr's steroid-sparing lung disease drug disappoints in late-stage trial FirstWord Pharma
- Why Is Atyr Pharma Stock Slipping Premarket? MSN
- ATyr Pharma's lung disease drug misses main goal in late-stage trial MarketScreener
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
9 min
vs 10 min read
Condensed
98%
1,843 → 41 words
Want the full story? Read the original article
Read on GlobeNewswire